<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00328770</url>
  </required_header>
  <id_info>
    <org_study_id>#4279</org_study_id>
    <nct_id>NCT00328770</nct_id>
  </id_info>
  <brief_title>De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma</brief_title>
  <official_title>De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma: Long-Term Outcomes and Side Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates whether sirolimus could decrease the rate of hepatoma recurrence
      after liver transplantation in high risk hepatoma patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 70 patients with HCC (mean age: 54.6 years, female/male: 12/58) received a liver
      transplant and were included in the study. Immunosuppression included de novo sirolimus,
      low-dose calcineurin inhibitor for 6 to 12 months, with short-course (3 months) or no
      steroids.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1996</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Surviving at One and Four Years After Liver Transplant</measure>
    <time_frame>1 &amp; 4 years</time_frame>
    <description>Percent of Patients Surviving at One &amp; Four years after Liver Transplant was calculated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Surviving With no Evidence of Recurrent Tumor at One and Four Years After Liver Transplant</measure>
    <time_frame>1 and 4 years</time_frame>
    <description>Percentage of Participants Surviving with no Evidence of Recurrent Hepatocellular Carcinoma at One and Four Years After Liver Transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sirolimus Toxicity/Intolerance</measure>
    <time_frame>1 year</time_frame>
    <description>Sirolimus toxicity/intolerance requiring discontinuation of sirolimus</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Liver Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sirolimus based immunosuppression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sirolimus given intravenously or orally to achieve serum level of 12-20ug/l</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Sirolimus given intravenously or orally to achieve target levels of 12-20ug/l</description>
    <arm_group_label>Sirolimus based immunosuppression</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with hepatocellular (HCC) carcinoma receiving liver transplant

        Exclusion criteria:

          -  Patients less than 18 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman M Kneteman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2006</study_first_submitted>
  <study_first_submitted_qc>May 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2006</study_first_posted>
  <results_first_submitted>June 12, 2012</results_first_submitted>
  <results_first_submitted_qc>August 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 1, 2012</results_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Norman Kneteman</investigator_full_name>
    <investigator_title>Co-zone Clinical Section Chief, Transplants/NARP</investigator_title>
  </responsible_party>
  <keyword>liver transplant</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>sirolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All adults receiving a liver transplant between December 1996 and March 2006 who had hepatocellular carcinoma and were treated with sirolimus as part of their immunosuppression after their transplant were included in this trial.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>All Study Patients</title>
          <description>All patients with hepatocellular carcinoma receiving sirolimus-based immunosuppression after liver transplantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Patients</title>
          <description>All patients with hepatocellular carcinoma receiving sirolimus-based immunosuppression after liver transplantation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.6" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Surviving at One and Four Years After Liver Transplant</title>
        <description>Percent of Patients Surviving at One &amp; Four years after Liver Transplant was calculated</description>
        <time_frame>1 &amp; 4 years</time_frame>
        <population>Percentage of patients surviving to 1 and 4 years after liver transplant was calculated for all patients</population>
        <group_list>
          <group group_id="O1">
            <title>Patient Survival</title>
            <description>1 and 4 year patient survival</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Surviving at One and Four Years After Liver Transplant</title>
          <description>Percent of Patients Surviving at One &amp; Four years after Liver Transplant was calculated</description>
          <population>Percentage of patients surviving to 1 and 4 years after liver transplant was calculated for all patients</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 year patient survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 year patient survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Surviving With no Evidence of Recurrent Tumor at One and Four Years After Liver Transplant</title>
        <description>Percentage of Participants Surviving with no Evidence of Recurrent Hepatocellular Carcinoma at One and Four Years After Liver Transplant</description>
        <time_frame>1 and 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Study Patients</title>
            <description>All patients with hepatocellular carcinoma receiving sirolimus-based immunosuppression after liver transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Surviving With no Evidence of Recurrent Tumor at One and Four Years After Liver Transplant</title>
          <description>Percentage of Participants Surviving with no Evidence of Recurrent Hepatocellular Carcinoma at One and Four Years After Liver Transplant</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 year tumor-free survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 year tumor-free survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sirolimus Toxicity/Intolerance</title>
        <description>Sirolimus toxicity/intolerance requiring discontinuation of sirolimus</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Study Patients</title>
            <description>All patients with hepatocellular carcinoma receiving sirolimus-based immunosuppression after liver transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Sirolimus Toxicity/Intolerance</title>
          <description>Sirolimus toxicity/intolerance requiring discontinuation of sirolimus</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Only Adverse Events related to toxicity were collected/reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Study Patients</title>
          <description>All patients with hepatocellular carcinoma receiving sirolimus-based immunosuppression after liver transplantation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematological toxicity</sub_title>
                <description>Anemia defined as hemoglobin under 8 g/dL for at least one week or requiring treatment. Leucopenia defined as leukocyte counts under 3 x 10-9/L for at least 5 days or requiring granulocyte colony-stimulating factor therapy.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Delayed wound healing</sub_title>
                <description>Delayed wound healing defined as a wound still requiring nursing therapy one month after surgery.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mouth ulcers</sub_title>
                <description>Oral ulcers necessitating patients being discontinued from sirolimus therapy</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other unspecified reasons for discontinuation of sirolimus</sub_title>
                <description>Reasons patients were discontinued from sirolimus therapy were not specified by the physicians who took the patients off the medication.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dyslipidemia</sub_title>
                <description>Dyslipidemia necessitating patient have sirolimus discontinued.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Norman Kneteman</name_or_title>
      <organization>Liver Transplant Program, University of Alberta Hospitals</organization>
      <phone>780-407-6168</phone>
      <email>norm.kneteman@albertahealthservices.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

